Skip to main content
Signal8

AVENUE THERAPEUTICS, INC. (ATXI)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc.

OTC:ATXIHealthcare
-8.29%$0.2800
CLOSED
Mkt Cap$923K
EV-
Float2.85M
O/S3.29M
VOL3K sh
$ Vol$798
RVOL1.01×
Inst Own-
Net Cash/Sh-
Dilution
Avenue Therapeutics, Inc. logoOTC:ATXIClosed$0.2800-8.29%
Historical Data
DateOpenHighLowCloseVolume
Nov 12, 20260.28000.28000.28000.28002,828
Nov 9, 20260.28000.42890.28000.30531,129
Nov 5, 20260.42890.42890.42890.4289117
Nov 2, 20260.40190.40190.40190.40192,097
Oct 30, 20260.42790.42790.42790.4279301
Oct 28, 20260.38000.38000.38000.38005,007
Oct 27, 20260.41700.41700.39850.39852,115
Oct 26, 20260.40180.41230.40000.412313,998
Oct 23, 20260.38500.38500.38500.3850234
Oct 20, 20260.40420.40420.40420.4042104
Oct 14, 20260.43000.43000.43000.4300329
Oct 13, 20260.44030.44030.42000.42003,036
Oct 12, 20260.44900.44900.40050.4005488
Oct 8, 20260.42980.42980.42980.4298249
Oct 7, 20260.38160.44900.38160.44906,121
Oct 5, 20260.38000.38000.38000.3800604
Oct 2, 20260.40760.40760.40760.40761,083
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
1
HOLD
0
SELL
0
TOTAL1
Insider Trades
InsiderTypeShares
Fortress Biotech, Inc. profile photoFortress Biotech, Inc.Grant/Award111.2K
Fortress Biotech, Inc. profile photoFortress Biotech, Inc.Grant/Award33.7K
Herskowitz Neil profile photoHerskowitz NeilSale23
KRANZLER JAY D profile photoKRANZLER JAY DSale61
KRANZLER JAY D profile photoKRANZLER JAY DPurchase497
KRANZLER JAY D profile photoKRANZLER JAY DPurchase3
Shareholders
0.0%
Institutional
(0)
7.2%
Insiderⓘ
(4)
20.9%
5%+ Owners
(4)
of which 0.5% rests on schedules older than 24 months (1 holder)
72.0%
Unattributed (incl. retail)ⓘ
Insider7.2%
5%+ Beneficial20.9%
Unattributed (incl. retail)72.0%
Sources: Form 4, 13D/13GO/S: 3.3M · as of 4 Nov 2026 · SEC filings
Insiders & Institutional Holders

Insiders

About

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Key Metrics
Market Cap$922,591
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateJun 27, 2017
Shares Outstanding3.29M
Authorized Shares
Float2.85M
52-Week Range
$0.1500$0.9570
$0.2800(16th percentile)
Volume
Average Daily Volume2.79K
2.83K today vs 2.79K avg(+1%)

30d Avg

2.79K

60d Avg

4.37K

90d Avg

9.03K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of ATXI as of Sep 30, 2026 records 3 outstanding warrant series, from SEC filings. Avenue Therapeutics, Inc. (OTC: ATXI) traded at $0.2800 on Nov 12, 2026, down 8.29% from the previous close of $0.3053. 52-week range: $0.1500 to $0.9570. The company is in the Healthcare sector (Biotechnology).